Tenofovir Disoproxil Fumarate Patent Expiration
Tenofovir Disoproxil Fumarate is used for managing chronic hepatitis B and HIV infections in both adults and pediatric patients. It was first introduced by Gilead Sciences Inc
Tenofovir Disoproxil Fumarate Patents
Given below is the list of patents protecting Tenofovir Disoproxil Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Viread |
US5922695 (Pediatric) | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Viread |
US5935946 (Pediatric) | Nucleotide analog composition and synthesis method |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Viread |
US5977089 (Pediatric) | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Viread |
US6043230 (Pediatric) | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Viread | US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
| Viread | US5935946 | Nucleotide analog composition and synthesis method |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
| Viread | US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
| Viread | US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
Tenofovir Disoproxil Fumarate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Tenofovir Disoproxil Fumarate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study | National Institute of Allergy and Infectious Diseases (NIAID) | NA |
RECRUITING
(Sep 9, 2026)
| PHASE2 |
| Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection | Carlos Brites | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |
| Bioequivalence Study of Tenofovir Disoproxil Fumarate Tablets in Healthy Chinese Subjects | Haisco Pharmaceutical Group Co., Ltd. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |